Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study
Authors' conclusion
GAHT discontinuation is uncommon when therapy follows Endocrine Society guidelines. Future research should include prospective studies with long-term follow-up of individuals receiving GAHT.
Study context
- Population
- Transgender and gender diverse (TGD) individuals prescribed estradiol or testosterone between January 1, 2000, and January 1, 2019, at academic centers; 231 (60%) assigned male at birth, 154 (40%) assigned female at birth
- Participants
- 385 eligible participants
- Exposure
- Pediatric vs Adult
- Pediatricn = 121
- Adultn = 264
- Outcome
- Incidence and determinants of GAHT discontinuation
- Follow-up
- Average of 4 years (maximum 19 years) since GAHT initiation
Methodological detailsacademic centers, 2-phase process, Kaplan-Meier survival analyses
- Academic centers
- 2-phase process
- Kaplan-Meier survival analyses
Main finding
As reported in the abstract
GAHT discontinuation · during follow-up
Discontinued gender-affirming hormone therapy (GAHT) during follow-up (phase 1)
6 participants
1.6%
Observational data: associations, not effects.
Original publication
Adherence to Gender Affirming Hormone Therapy in Transgender Adolescents and Adults: A Retrospective Cohort Study. J Clin Endocrinol Metab. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →